ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
01. März 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
29. Februar 2024 08:00 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
28. Februar 2024 16:45 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
21. Februar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
24. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro tillkännager sin första EU MDR-certifiering och godkännande att skicka produkter till Europa
22. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (”Företaget”), ett globalt företag inom medicinteknik och cell- och genterapi som erbjuder exakt...
ClearPoint Neuro gibt erste erfolgreiche EU-MDR-Zertifizierung und Genehmigung zur Lieferung von Produkten nach Europa bekannt
22. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein weltweit tätiges Unternehmen im Bereich Medizinprodukte sowie Zell- und...
ClearPoint Neuro annonce être arrivé pour la première fois au terme du processus de certification de conformité au Règlement européen MDR et obtenu l’autorisation d’expédier son produit en Europe
22. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 22 janv. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT (la « Société »), une entreprise internationale spécialisée dans les dispositifs médicaux, les...
ClearPoint Neuro annoncerer første EU MDR certificeringssucces og godkendelse til at sende produkt til Europa
22. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) ("Virksomheden"), en global enhed, celle- og genterapi-virksomhed, der tilbyder præcis navigation...
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
22. Januar 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.